Pierre Giglio, MD
- Director, Division of Neuro-Oncology
The experts at the Division of Neuro-Oncology are transforming the way brain and spine tumors are prevented, detected and treated. We deliver a full range of research-based, interdisciplinary and comprehensive care for patients with all forms of brain and spine cancer. Our subspecialists are world-renowned authorities in neuro-oncology, surgery, radiology and research who work together to devise optimal treatment plans for each patient’s biologically unique cancer. Innovative clinical trials and groundbreaking research often lead to the most advanced treatments offered anywhere. We benefit from a wealth of resources available to us as part of an academic medical center, a National Cancer Institute (NCI)-designated Comprehensive Cancer Center and a freestanding cancer hospital, all located on the main campus of one of the nation’s largest universities.
Treating nervous system cancers requires a management approach that includes not just one physician but a team of specialists, including neurosurgeons, radiation oncologists, pathologists, neuroimaging specialists and more working in a collaborative environment. Our team uses innovative technologies to perform genetic and molecular analysis of brain and other central nervous system tumors. The combination of our expertise and technological capabilities means patients receive individualized and targeted treatment plans for their specific needs. Our residency and fellowship programs are competitive, in demand, and provide opportunities for lasting and meaningful research.
The goal of the Division is to improve survival and the quality of life for patients with brain and nervous system cancers with the ultimate goal of eradicating these cancers altogether through a dedicated research effort.
Our many clinical trials test the effectiveness of novel therapeutics and treatments in slowing and stopping the growth of brain and spine malignancies.
Alnahhas I, Rayi A, Thomas D, Ong S, Giglio P, Puduvalli V. False-positive 1p/19q Testing Results in Gliomas: Clinical and Research Consequences. Am J Clin Oncol. 2020 Nov; 43(11):802-805.
Alnahhas I, Rayi A, Ong S, Giglio P, Puduvalli V. Management of gliomas in patients with Lynch syndrome. Neuro Oncol. 2021 Jan 30;23(1):167-168.
Alnahhas I, Alsawas M, Rayi A, Palmer JD, Raval R, Ong S, Giglio P, Murad HM, Puduvalli V. Characterizing benefit from temozolomide in MGMT promoter unmethylated and methylated glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020 Oct 30;2(1):vdaa082.
Wang JL, Barth RF, Cavaliere R, Puduvalli VK, Giglio P, Lonser RR, Elder JB. Phase I trial of intracerebral convection-enhanced delivery of carboplatin for treatment of recurrent high-grade gliomas. PLoS One. 2020 Dec 29;15(12):e0244383.
Alnahhas I, Rayi A, Palmer JD, Raval R, Folefac E, Ong S, Giglio P, Puduvalli V. The role of VEGF receptor inhibitors in preventing cerebral radiation necrosis: a retrospective cohort study. Neurooncol Pract. 2020 Oct 17;8(1):75-80.
Eltobgy M, Huntoon K, Musgrave N, Shaikhouni A, Hardesty DA, Giglio P, Elder JB. Impact of cerebrospinal fluid flow study in patients undergoing intrathecal chemotherapy via ventricular catheter reservoir. J Neurooncol. 2021 May;153(1):161-167.
Alnahhas I, LaHaye S, Giglio P, Mardis E, Puduvalli V. An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma. Neurooncol Adv. 2020 Nov 16;2(1):vdaa117.